Parag Saxena reports Reviva (RVPH) stake at 2.8%, below 5% level

Rhea-AI Filing Summary

Reviva Pharmaceuticals Holdings, Inc. investor Parag Saxena filed an amended Schedule 13D reporting beneficial ownership of 363,280 shares of common stock, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. His holdings include directly owned shares, interests held through various Vedanta-related entities, shares underlying warrants and pre-funded warrants, and fully vested options exercisable within 60 days of the filing date. The filing states that Saxena ceased to be a beneficial owner of more than five percent of Reviva’s common stock on March 20, 2026, and that he has not effected any transactions in the issuer’s securities during the 60 days preceding this amendment.

Insights

Equity ownership and governance analyst

Key Reviva holder now reports a smaller, sub‑5% position.

Parag Saxena now reports beneficial ownership of 363,280 Reviva shares, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. This reflects a move from previously holding above the 5% reporting threshold.

The position spans directly owned stock, entity-held shares, and securities convertible within 60 days, including warrants, pre-funded warrants, and vested options. The filing notes no transactions in the issuer’s securities during the 60 days before this amendment.

Saxena is no longer classified as a more-than-5% beneficial owner as of March 20, 2026. Future company filings may clarify any further changes in ownership structure or additional amendments if his stake shifts materially again.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 13)

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

76152G209

(CUSIP Number)

Parag Saxena
Vedanta Management, L.P.,, 250 West 55th Street, Ste 16C
New York, NY, 10019
212-710-5220

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/20/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 76152G209

1

Name of reporting person

Parag Saxena

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF, WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

INDIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 45,047.00
8	Shared Voting Power 318,233.00
9	Sole Dispositive Power 45,047.00
10	Shared Dispositive Power 318,233.00

11

Aggregate amount beneficially owned by each reporting person

363,280.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.8 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 5 for additional information.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value
(b)	Name of Issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC.
(c)	Address of Issuer's Principal Executive Offices: Vedanta Management, L.P., 250 West 55th Street, Ste 16C, New York, NEW YORK , 10019.
Item 1 Comment: This Amendment No. 13 to Schedule 13D (this "Amendment No. 13"), filed on behalf of Parag Saxena (the "Reporting Person"), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, Amendment No. 4 on June 3, 2021, Amendment No. 5 on September 12, 2022, Amendment No. 6 on November 30, 2023, Amendment No. 7 on May 31, 2024, Amendment No. 8 on August 23, 2024, Amendment No. 9 on January 31, 2025, Amendment No. 10 on July 1, 2025, Amendment No. 11 on September 24, 2025, and Amendment No. 12 on December 22, 2025 (as amended, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 13 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	The information set forth in rows 11 and 13 of the cover page to this Amendment No. 13 are incorporated by reference into this Item 5. The percentage set forth in row 13 of the cover page is based on 12,810,377 outstanding shares of common stock, par value $0.0001 per share ("Common Stock"), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the "Issuer"), as of March 20, 2026, as reported directly by the Issuer to the Reporting Person.
(b)	The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 13 is incorporated by reference. The 363,280 shares of Common Stock reported as beneficially owned on this Amendment No. 13 by Mr. Saxena consist of the following: (i) 45,047 shares of Common Stock held directly, (ii) 46,550 shares of Common Stock held by Vedanta Associates-R, (iii) 19,950 shares of Common Stock held by Beta Operators, (iv) 4,977 shares of Common Stock held by Vedanta Associates, (v) 60,605 shares of Common Stock underlying warrants held by Vedanta Associates-R, (vi) 58,442 shares of Common Stock underlying warrants held by Beta Operators, (vii) 29,269 shares of Common Stock underlying warrants held by Vedanta R2, (viii) 25,692 shares of Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (ix) 43,479 shares of Common Stock underlying pre-funded warrants held by Beta Operators, (x) 29,269 shares of Common Stock underlying pre-funded warrants held by Vedanta R2, and (xi) 1,480 underlying options that are fully vested as of March 24, 2026 (the "Filing Date"). As a result, Mr. Saxena is deemed to beneficially own approximately 2.8% of the outstanding shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially owned by Mr. Saxena exclude 410 shares underlying options that are unvested as of 60 days of the Filing Date. In accordance with Rule 13d-3, the beneficial ownership percentage for the Reporting Person assumes that the warrants and options that can be exercised within 60 days of the Filing Date, if any, held by the Reporting Person have been exercised, and that no other warrants or options have been exercised.
(c)	The Reporting Person has not effected any transactions during the past sixty (60) days from the date of this filing in any securities of the Issuer.
(d)	Except as otherwise reported herein, no person or entity other than the Reporting Person has the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common Stock reported on this Schedule 13D.
(e)	The Reporting Person ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock on March 20, 2026.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Parag Saxena

Signature:	/s/ Parag Saxena
Name/Title:	Parag Saxena/Individual
Date:	03/24/2026

FAQ

What percentage of Reviva Pharmaceuticals (RVPH) does Parag Saxena currently beneficially own?

Parag Saxena beneficially owns about 2.8% of Reviva’s common stock. This corresponds to 363,280 shares out of 12,810,377 outstanding shares as of March 20, 2026, as reported directly by the company to him.

How many Reviva Pharmaceuticals (RVPH) shares does Parag Saxena report owning in total?

He reports beneficial ownership of 363,280 shares of Reviva common stock. This total includes directly held shares, interests through Vedanta-related entities, and shares underlying warrants, pre-funded warrants, and fully vested options exercisable within 60 days.

Has Parag Saxena recently traded Reviva Pharmaceuticals (RVPH) stock?

The filing states that Parag Saxena has not effected any transactions in Reviva securities during the 60 days prior to the amendment’s filing date. The updated ownership reflects his current beneficial holdings rather than recent trading activity.

When did Parag Saxena cease being a 5% beneficial owner of Reviva (RVPH)?

The filing reports that Parag Saxena ceased to be a beneficial holder of more than five percent of Reviva’s common stock on March 20, 2026. After that date, his reported ownership stands at approximately 2.8% of outstanding shares.

What components make up Parag Saxena’s Reviva (RVPH) beneficial ownership?

His beneficial ownership includes 45,047 shares held directly plus shares and underlying securities held via Vedanta entities, such as warrants, pre-funded warrants, and vested options exercisable within 60 days of the March 24, 2026 filing date.

What share count did Reviva (RVPH) report outstanding for calculating Saxena’s 2.8% stake?

Reviva reported 12,810,377 outstanding shares of common stock as of March 20, 2026. This figure, provided directly to Parag Saxena, was used to calculate his 2.8% beneficial ownership disclosed in the amended Schedule 13D.